5, 2015 – – Chemotherapy at the start of hormone therapy can lengthen the lives of males with prostate cancer that has pass on beyond the gland, a fresh study finds. Over 29 months of follow-up nearly, men with advanced prostate cancer who received the mixture therapy lived almost 14 months longer than men who received only hormone therapy , researchers said. ‘Men who have hormone-sensitive metastatic prostate tumor should speak with their doctors about having this mixture treatment to significantly prolong their survival,’ said lead researcher Dr. Christopher Sweeney, an associate professor of medication at Harvard Medical College. For 50 years, hormone therapy has been the standard care for these sufferers, he said.Physicians retiring early. Small methods bankrupted by up-front expenditures or locked into ineffective systems by the prohibitive cost of switching. Hours consumed by onerous data entry unrelated to patient care. Workflow disruptions. And most importantly, massive intrusions on our patient relationships. These complaints might be dismissed as developing pains, born of resistance to improve. But transitional chaos should be distinguished from enduring harm.